Abstracts tagged "Outcome measures"

Abstract Number: 1401 • ACR Convergence 2023
The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA
Gonul Hazal Koc¹, Marc r. Kok², Jolanda J. Luime¹, ilja Tchetverikov³, William R Tillett⁴, Fazira R. Kasiem¹, Lindy A. Korswagen⁵, J. Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Maikel van oosterhout⁸, P. Baudoin⁹, Petra Kok¹⁰, radboud J.e.m. Dolhain¹¹ and marijn vis¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands, ⁴Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, Rotterdam, Netherlands, ⁷Haga Ziekenhuis, The Hague, Netherlands, ⁸Groene Hart Ziekenhuis, Gouda, Netherlands, ⁹Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ¹⁰Reinier de Graaf Gasthuis, Delft, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: A feasible, widely accepted, comprehensive disease activity measure is needed for daily use in psoriatic arthritis (PsA). Current measures are either complex (Psoriatic Arthritis…
Abstract Number: 1641 • ACR Convergence 2023
The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?
Selinde Snoeck Henkemans¹, Pascal de Jong¹, Jolanda J. Luime¹, Marc r. Kok², ilja Tchetverikov³, Annette van der Helm-van Mil⁴ and marijn vis¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In rheumatoid arthritis (RA), initiation of treatment within the window of opportunity, i.e. 12 weeks after symptom onset, results in higher remission rates, and…
Abstract Number: 2060 • ACR Convergence 2023
Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology
Alana Haussmann¹, Lauren Taylor-Maloney², Ingrid Pan², Katherine Nowicki³, JoAnn Zell⁴ and Katharine Moore⁵, ¹University of Colorado Internal Medicine Residency, Denver, CO, ²Children's Hospital Colorado, Aurora, CO, ³University of Colorado, Lakewood, CO, ⁴University of Colorado Anschutz Medical Campus, Denver, CO, ⁵University of Colorado / Children's Hospital Colorado, Aurora, CO
Background/Purpose: The transfer of care from pediatric to adult rheumatology (AR) is a complex process dependent on communication between medical teams within and across institutions,…
Abstract Number: 2334 • ACR Convergence 2023
Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Ronald van Vollenhoven¹, Eric Morand², Richard A. Furie³, Kenneth Kalunian⁴, Raj Tummala⁵, Gabriel Abreu⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁶, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴University of California San Diego, La Jolla, CA, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, remission is an established therapeutic goal associated with reduced damage accrual and flares, and improved health-related quality of life.1 Here,…
Abstract Number: PP17 • ACR Convergence 2023
Utilizing Support Networks to Improve Patient Outcomes
Brian Vogel, Lupus and Allied Diseases Association, Inc., San Diego, CA
Background/Purpose: In 2006, I realized I was gay and identified as LGBTQIA but did not come out. In 2008, I began experiencing chronic widespread pain,…
Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Heather Lapidus Glassner and Elizabeth Luce, MyHealthTeam, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…
Abstract Number: 0807 • ACR Convergence 2023
Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records
David Cheng¹, Dana Weisenfeld², Kumar Dahal², Qing Liu², Vidul Ayakulangara Panickan³, Mary Jeffway², Thany Seyok², Gregory McDermott², Michael Weinblatt⁴, Nancy Shadick⁵, Tianxi Cai⁶ and Katherine Liao², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Real-world data including electronic health records (EHRs) are a promising resource for learning to optimize treatment strategies for rheumatoid arthritis (RA). A major challenge…
Abstract Number: 1152 • ACR Convergence 2023
Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital
Fabricio Benavides¹, Monica Renuncio-García¹, Salma Al Fazazi², clara escagedo Cagigas¹, maria rodriguez Vidriales¹, Vanesa Calvo Río³, Juan Irure-Ventura¹, luis martin penagos⁴, Marcos Lopez-Hoyos⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Puerta Del Mar, Cádiz, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of pathologies characterized by necrotizing inflammation that mainly affects small and medium-sized vessels. Serum anti-neutrophil cytoplasmic antibodies (ANCA),…
Abstract Number: 1407 • ACR Convergence 2023
Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA
Dafne Capelusnik¹, Sofia Ramiro², Elena Nikiphorou³, Walter P. Maksymowych⁴, Marina Nighat Magrey⁵, Helena Marzo-Ortega⁶ and Annelies Boonen⁷, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³King's College London, London, United Kingdom, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Case Western Reserve University, University Hospitals, Cleveland, OH, ⁶NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…
Abstract Number: 1669 • ACR Convergence 2023
High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study
Arthur Mageau¹, Alois Helary², Stephane Ruckly³, Andrey Strukov², Thomas Papo¹, Jean-Francois Timsit¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³INSERM, Paris, France
Background/Purpose: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Previous studies have shown that immune dysregulation associated with severe…
Abstract Number: 2107 • ACR Convergence 2023
Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study
Nicholas Wiemer¹, Yue Yin² and Tarun Sharma¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allegheny Health Network Singer Research Institute, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and potentially debilitating disease.Social determinants, including smoking and depression, have been shown to be linked to worse clinical…
Abstract Number: 2374 • ACR Convergence 2023
Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis
Balazs Odler¹, Regina Riedl¹, Jacinta Lee², Laura Cooney³, Peter Merkel⁴, William St.Clair⁵, Duvuru Geetha⁶, Paul Monach⁷, David Jayne², Rona Smith², Paul A. Lyons², Mark Little⁸, Salem Almaani⁹, Alexander Rosenkranz¹, Ulrich Specks¹⁰, John Stone¹¹ and Andreas Kronbichler¹², ¹Medical University of Graz, Graz, Austria, ²University of Cambridge, Cambridge, United Kingdom, ³Immune Tolerance Network, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University Medical Center, Durham, NC, ⁶Johns Hopkins University, Baltimore, MD, ⁷VA Boston Healthcare System, Boston, MA, ⁸Trinity College Dublin, Dublin, Ireland, ⁹Ohio State University Medical Center, Columbus, OH, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ¹²Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria
Background/Purpose: ANCA-associated vasculitis (AAV) is a life-threatening disorder characterized by a relapsing-remitting disease course necessitating immunosuppression to control disease activity. Balancing the risks of infection…
Abstract Number: 0342 • ACR Convergence 2023
Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey
Lourdes Perez-Chada¹, George Gondo², Joseph F. Merola³ and Alice B. Gottlieb⁴, ¹Brigham and Women's Hospital, Boston, MA, ²National Psoriasis Foundation, Alexandria, VA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: The IDEOM MSK-Q aims to assess MSK symptoms in individuals with psoriatic disease. It consists of 3 subscales: Intensity of MSK Symptom (3 items),…
Abstract Number: 0825 • ACR Convergence 2023
A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)
Rachita Pandya¹, Joshua Dan², Julianne Kleitsch¹, Darosa Lim³, Barbara White⁴ and Victoria P. Werth⁵, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴SFJ Pharmaceuticals, Towson, MD, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Current clinical trials in dermatomyositis (DM) are largely focused on muscle improvement, and use the Total Improvement Score (TIS) as the primary efficacy measure.…
Abstract Number: 1162 • ACR Convergence 2023
Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies
Mamatha Gorijavolu¹, Chengappa Kavadichanda¹, Ramesh Ananthakrishnan¹, Christina Mariaselvam¹, Molly Thabah¹ and VS Negi², ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²All India Institute of Medical Sciences, Bilaspur, Puducherry, India
Background/Purpose: Muscle weakness in inflammatory myopathies (IIM) is due to muscle-edema, atrophy and fatty-infiltration among which edema is the predominant cause at baseline. Some IIM…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].